HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Harris, N. S. Articles by Najarian, J. S. Search for Related Content PubMed Articles by Harris, N. S. Articles by Najarian, J. S.

The Effect of Antiplasma Cell Sera on the Primary Immune Response¹

From The University of Minnesota Medical School, Surgery Department, Minneapolis, Minnesota

Abstract

An antiserum, antiplasma cell sera (APS), prepared against mouse myeloma cells was specifically cytotoxic to myeloma cells; the cytotoxicity could be absorbed out only with myeloma cells. When tested in a hemolytic plaque assay, APS greatly reduced the number of direct (IgM) plaque-forming cells (PFC) when administered 1, 2 or 3 days after immunization with sheep red blood cells (SRBC). The APS was also effective in vitro in reducing the number of direct PFC in spleen cell suspensions from mice that had been immunized 4 days earlier with SRBC. As determined in a skin allografting model, APS had no obvious effects on cellular immunity.

Footnotes

¹ This work was supported by United States Public Health Service Grants AM 13083 and AM 35580, American Cancer Society Grant T-428 and United States Public Health Service Contract NIH 69–2061.

² Postdoctoral Fellow. Present address: Transplantation and Immunology Division, Shriners Burns Institute, Galveston, Texas 77550.